Surfix Diagnostics develops diagnostic tests for the early detection and monitoring of cancer utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. To make it even more exciting: this photonic diagnostics platform is so versatile that it can be used for immunoassays AND for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available.

The core of Surfix’s photonic diagnostics platform is a photonic biosensor consisting of a photonic biochip and a microfluidic cartridge both optimized with Surfix's proprietary nanocoatings. The biosensor is used in combination with a dedicated desktop reader.

Biotechnology

Life Sciences

Medical Devices

Surfix Diagnostics

Jos Lunenberg

Nadieh Kuijpers

Henk Van Middendorp

Geert Besselink

Colin Bartel

Arthur Blom

The Research and Development team at Surfix Diagnostics is responsible for innovating and optimizing the company’s photonic diagnostics platform. This includes designing and developing photonic biochips, microfluidic cartridges, and bioreceptors for detecting biomarkers in liquid biopsies. The team works collaboratively to enhance the platform's capabilities for both immunoassays and molecular diagnostics, ensuring early and accurate cancer detection and monitoring.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Surfix Diagnostics

Leadership Team